Diverse Roles of Antibodies in Antibody–Drug Conjugates

Aiko Yamaguchi and H. Charles Manning

Pharmaceuticals, 2025, 18, 180
DOI: 10.3390/ph18020180

Translational Approaches for Human Pharmacokinetics and Pharmacodynamics Prediction of Antibody-drug Conjugates: Bridging Complexity from Bench to Bedside

Wenhang Xu, Chaohsuan Pan, Qingfeng He, Xiao Zhu and Xiaoqiang Xiang

Curr. Pharmacol. Rep., 2026, 12
DOI: 10.1007/s40495-026-00443-4

A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC

Aman P. Singh and Dhaval K. Shah

Journal of Pharmaceutical Sciences, 2019, 108, 2465
DOI: 10.1016/j.xphs.2019.01.034

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier

Brandon M. Bordeau, Lubna Abuqayyas, Toan D. Nguyen, Ping Chen and Joseph P. Balthasar

Front. Pharmacol., 2022, 13
DOI: 10.3389/fphar.2022.837744

A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects

Jackson K. Burton, Dean Bottino and Timothy W. Secomb

AAPS J, 2020, 22
DOI: 10.1208/s12248-019-0390-2

ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies

Nooshafarin Amani, Farid Abedin Dorkoosh and Hamid Mobedi

CDD, 2020, 17, 23
DOI: 10.2174/1567201816666191121145109

Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice

Alexander Kulesza, Claire Couty, Paul Lemarre, Craig J. Thalhauser and Yanguang Cao

J Pharmacokinet Pharmacodyn, 2024, 51, 581
DOI: 10.1007/s10928-024-09930-x

Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation

Chen Bai, Emily E. Reid, Alan Wilhelm, Manami Shizuka, Erin K. Maloney, Rassol Laleau, Lauren Harvey, Katie E. Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L. Miller, Ravi Chari, Thomas A. Keating and Nicholas C. Yoder

Bioconjugate Chem., 2020, 31, 93
DOI: 10.1021/acs.bioconjchem.9b00777

Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates

Eshita Khera and Greg M. Thurber

BioDrugs, 2018, 32, 465
DOI: 10.1007/s40259-018-0302-5

QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life

Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, Volker Engelhardt, Helena Vostiarova, John Davis, Nicolas Ebel, Kuno Wuersch, Vincent Romanet, Sherif Sharaby and Jeffrey D. Kearns

J Pharmacokinet Pharmacodyn, 2025, 52
DOI: 10.1007/s10928-024-09956-1

Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy

Ping Chen, Brandon M. Bordeau, Wenqiu Zhang and Joseph P. Balthasar

AAPS J, 2025, 27
DOI: 10.1208/s12248-025-01076-z

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to IncreaseIn VivoEfficacy

Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher Espelin, Neeraj Kohli, Bahar Matin, Yulius Setiady, Michael L. Miller, Thomas A. Keating, Ravi Chari, Jan Pinkas, Richard Gregory and Greg M. Thurber

Molecular Cancer Therapeutics, 2021, 20, 203
DOI: 10.1158/1535-7163.MCT-20-0451

Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Nalini Sathyanarayan, Jennifer Donnell, Serengulam V. Govindan and Greg M. Thurber

Molecular Cancer Therapeutics, 2024, 23, 343
DOI: 10.1158/1535-7163.MCT-23-0437

Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates

Francesco Giansanti, Emily Capone, Sara Ponziani, Enza Piccolo, Roberta Gentile, Alessia Lamolinara, Antonella Di Campli, Michele Sallese, Valentina Iacobelli, Annamaria Cimini, Vincenzo De Laurenzi, Rossano Lattanzio, Mauro Piantelli, Rodolfo Ippoliti, Gianluca Sala and Stefano Iacobelli

Journal of Controlled Release, 2019, 294, 176
DOI: 10.1016/j.jconrel.2018.12.018

Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates

Eshita Khera, Shujun Dong, Haolong Huang, Laureen de Bever, Floris L. van Delft and Greg M. Thurber

Molecular Cancer Therapeutics, 2022, 21, 310
DOI: 10.1158/1535-7163.MCT-21-0580

Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release

Chuanjie Chen, Yongzhang Pan, Na Zhang, Ting Yang, Jiaxin Shi, Bige Ren, Yonghan He and Xuan Zhang

Journal of Controlled Release, 2026, 392, 114695
DOI: 10.1016/j.jconrel.2026.114695

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology

Jared Weddell, Manoj S. Chiney, Sumit Bhatnagar, John P. Gibbs and Mohamad Shebley

Clinical Translational Sci, 2021, 14, 395
DOI: 10.1111/cts.12892

Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models

Ian Nessler, Eshita Khera, Steven Vance, Anna Kopp, Qifeng Qiu, Thomas A. Keating, Adnan O. Abu-Yousif, Thomas Sandal, James Legg, Lorraine Thompson, Normann Goodwin and Greg M. Thurber

Cancer Research, 2020, 80, 1268
DOI: 10.1158/0008-5472.CAN-19-2295

Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2–Positive Tumors

Bruna Menezes, Jennifer J. Linderman and Greg M. Thurber

Drug Metabolism and Disposition, 2022, 50, 8
DOI: 10.1124/dmd.121.000503

Key metrics to expanding the pipeline of successful antibody–drug conjugates

Ian Nessler, Bruna Menezes and Greg M. Thurber

Trends in Pharmacological Sciences, 2021, 42, 803
DOI: 10.1016/j.tips.2021.07.005

Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers

Georgina B Armstrong, Harriet Graham, Anthony Cheung, Hanieh Montaseri, Glenn A Burley, Sophia N Karagiannis and Zahra Rattray

Advanced Drug Delivery Reviews, 2025, 224, 115648
DOI: 10.1016/j.addr.2025.115648

Applications of Pharmacometrics in Antibody–Drug Conjugate Development

Xiaoliang Cheng, Shuangmin Ji, Yonghyun Lee and Haiyan Dong

Pharmaceutics, 2026, 18, 354
DOI: 10.3390/pharmaceutics18030354

Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment

Alfred Zippelius, Sara M. Tolaney, Paolo Tarantino, Joseph P. Balthasar and Greg M. Thurber

Nat Rev Cancer, 2025, 25, 925
DOI: 10.1038/s41568-025-00869-w

Mathematical modeling of the receptor-mediated endocytosis process of targeted therapeutic agents in drug delivery systems

Jong Hyuk Byun and Il Hyo Jung

Applied Mathematical Modelling, 2020, 79, 300
DOI: 10.1016/j.apm.2019.10.037

RECEPTOR-MEDIATED ENDOCYTOSIS MODELING OF ANTIBODY-DRUG CONJUGATES TO THE RELEASED PAYLOAD WITHIN THE INTRACELLULAR SPACE CONSIDERING TARGET ANTIGEN EXPRESSION LEVELS

Jong Hyuk Byun, Anna Park and Il Hyo Jung

jaac, 2020, 10, 1848
DOI: 10.11948/20190232

Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates

Matthew Giese, Paul D. Davis, Robert H. Woodman, Greg Hermanson, Alex Pokora and Melissa Vermillion

Bioconjugate Chem., 2021, 32, 2257
DOI: 10.1021/acs.bioconjchem.1c00429

A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression

Sarah B. Gitto, Margaret Whicker, Gareth Davies, Sushil Kumar, Krista Kinneer, Haineng Xu, Arthur Lewis, Srinivas Mamidi, Sergey Medvedev, Hyoung Kim, Judith Anderton, E. Jessica Tang, Benjamin Ferman, Steven Coats, Robert W. Wilkinson, Eric Brown, Daniel J. Powell and Fiona Simpkins

Clinical Cancer Research, 2024, 30, 1567
DOI: 10.1158/1078-0432.CCR-23-1079

Development of and insights from systems pharmacology models of antibody‐drug conjugates

Inez Lam, Venkatesh Pilla Reddy, Kathryn Ball, Rosalinda H. Arends and Feilim Mac Gabhann

CPT Pharmacom & Syst Pharma, 2022, 11, 967
DOI: 10.1002/psp4.12833

Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer

François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada and Guilherme Nader-Marta

Expert Opinion on Drug Metabolism & Toxicology, 2024, 20, 45
DOI: 10.1080/17425255.2024.2302460

“Standing by” for Bystander Effects: Dual-Isotope Imaging of Antibody–Drug Conjugate and Payload Distribution

Cornelius Cilliers and Greg M. Thurber

J Nucl Med, 2018, 59, 1459
DOI: 10.2967/jnumed.118.213389

Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression

N. Ezgi Wood, Anıl Cengiz, Ming Gao, Alexander V. Ratushny, Ronny Straube and Marc R Birtwistle,

PLoS Comput Biol, 2025, 21, e1012839
DOI: 10.1371/journal.pcbi.1012839

Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics

Shujun Dong, Ian Nessler, Anna Kopp, Baron Rubahamya and Greg M. Thurber

Front. Pharmacol., 2022, 13
DOI: 10.3389/fphar.2022.836925

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

Christina Vasalou, Theresa A. Proia, Laura Kazlauskas, Anna Przybyla, Matthew Sung, Srinivas Mamidi, Kim Maratea, Matthew Griffin, Rebecca Sargeant, Jelena Urosevic, Anton I. Rosenbaum, Jiaqi Yuan, Krishna C. Aluri, Diane Ramsden, Niresh Hariparsad, Rhys D.O. Jones and Jerome T. Mettetal

CPT Pharmacom & Syst Pharma, 2024, 13, 994
DOI: 10.1002/psp4.13133

Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin

Ping Chen, Brandon M. Bordeau, Yu Zhang and Joseph P. Balthasar

Molecular Cancer Therapeutics, 2022, 21, 1573
DOI: 10.1158/1535-7163.MCT-22-0192

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates

Yangyang Gao, Yuwei Xia, Yixin Chen, Shiqi Zhou, Yingying Fang, Jieru Yu, Leyin Zhang and Leitao Sun

Front. Oncol., 2025, 14
DOI: 10.3389/fonc.2024.1459368

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation

Kenta Haraya, Haruka Tsutsui, Yasunori Komori and Tatsuhiko Tachibana

Pharmaceuticals, 2022, 15, 508
DOI: 10.3390/ph15050508

Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy

Brandon M. Bordeau, Yujie Yang and Joseph P. Balthasar

Cancer Research, 2021, 81, 4145
DOI: 10.1158/0008-5472.CAN-20-3822

Exploring Experimental and In Silico Approaches for Antibody–Drug Conjugates in Oncology Therapies

Vitor Martins de Almeida, Milena Botelho Pereira Soares and Osvaldo Andrade Santos-Filho

Pharmaceuticals, 2025, 18, 1198
DOI: 10.3390/ph18081198

Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer

Chih-Wei Lin

Am J Cancer Res, 2025, 15, 3817
DOI: 10.62347/FOWU3488

A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation

Nicholas C. Yoder, Chen Bai, Daniel Tavares, Wayne C. Widdison, Kathleen R. Whiteman, Alan Wilhelm, Sharon D. Wilhelm, Molly A. McShea, Erin K. Maloney, Olga Ab, Lintao Wang, Shan Jin, Hans K. Erickson, Thomas A. Keating and John M. Lambert

Mol. Pharmaceutics, 2019, 16, 3926
DOI: 10.1021/acs.molpharmaceut.9b00529

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Michael Samarkos, Helen Gogas and Dimitrios C. Ziogas

Vaccines, 2021, 9, 1111
DOI: 10.3390/vaccines9101111

An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens

Bruna Menezes, Cornelius Cilliers, Timothy Wessler, Greg M. Thurber and Jennifer J. Linderman

AAPS J, 2020, 22
DOI: 10.1208/s12248-019-0391-1

Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody

Bruna Menezes, Eshita Khera, Melissa Calopiz, Michael D. Smith, Michelle L. Ganno, Cornelius Cilliers, Adnan O. Abu-Yousif, Jennifer J. Linderman and Greg M. Thurber

AAPS J, 2022, 24
DOI: 10.1208/s12248-022-00756-4

Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data

Baron Rubahamya, Shujun Dong and Greg M. Thurber

Sci. Adv., 2024, 10
DOI: 10.1126/sciadv.adk1894

Modeling to capture bystander-killing effect by released payload in target positive tumor cells

Jong Hyuk Byun and Il Hyo Jung

BMC Cancer, 2019, 19
DOI: 10.1186/s12885-019-5336-7

Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping

Eshita Khera, Cornelius Cilliers, Michael D. Smith, Michelle L. Ganno, Katharine C. Lai, Thomas A. Keating, Anna Kopp, Ian Nessler, Adnan O. Abu-Yousif and Greg M. Thurber

Neoplasia, 2021, 23, 210
DOI: 10.1016/j.neo.2020.12.001

Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models

Ryo Tsumura, Takahiro Anzai, Yoshikatsu Koga, Hiroki Takashima, Yasuhiro Matsumura and Masahiro Yasunaga

Cancer Science, 2024, 115, 3986
DOI: 10.1111/cas.16335

Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting

Reginald Evans and Greg M. Thurber

Sci Rep, 2022, 12
DOI: 10.1038/s41598-022-11648-0

Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation

Aman P. Singh, Leiming Guo, Ashwni Verma, Gloria Gao-Li Wong, Greg M. Thurber and Dhaval K. Shah

AAPS J, 2020, 22
DOI: 10.1208/s12248-019-0387-x

Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)

Bruna Scheuher, Khem Raj Ghusinga, Kimiko McGirr, Maksymilian Nowak, Sheetal Panday, Joshua Apgar, Kalyanasundaram Subramanian and Alison Betts

J Pharmacokinet Pharmacodyn, 2024, 51, 429
DOI: 10.1007/s10928-023-09884-6

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Kevin Beaumont, Andy Pike, Michael Davies, Adriana Savoca, Christina Vasalou, Steffi Harlfinger, Diane Ramsden, Douglas Ferguson, Niresh Hariparsad, Owen Jones and Dermot McGinnity

Xenobiotica, 2022, 52, 770
DOI: 10.1080/00498254.2022.2141667

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Serengulam V. Govindan, Jennifer Donnell and Greg M. Thurber

Molecular Cancer Therapeutics, 2023, 22, 102
DOI: 10.1158/1535-7163.MCT-22-0375

Bystander effect of antibody–drug conjugates: fact or fiction?

Federica Giugliano, Chiara Corti, Paolo Tarantino, Flavia Michelini and Giuseppe Curigliano

Curr Oncol Rep, 2022, 24, 809
DOI: 10.1007/s11912-022-01266-4